Research Article
BibTex RIS Cite

Kanser Hastalarında COVID-19 Bilgisayarlı Tomografi, Klinik ve Laboratuvar Bulgularının Değerlendirilmesi

Year 2020, Volume: 22 Issue: Special Issue, 56 - 60, 30.11.2020

Tolga Köşeci Ömer Kaya Okan Dilek İrfan Alişan Veysel Haksöyler Berna Bozkurt Duman Timuçin Çil

https://doi.org/10.18678/dtfd.795333

Abstract

Amaç: Bu çalışmanın amacı kanser hastalarında koronavirus hastalığı 2019 (coronavirus disease 2019, COVID-19) bilgisayarlı tomografi (BT), klinik ve laboratuvar bulgularının değerlendirilmesi ve polimeraz zincir reaksiyonu (polymerase chain reaction, PCR) pozitif ve negatif hastaların bulgularının karşılaştırılmasıdır.
Gereç ve Yöntemler: Çalışmaya PCR testi pozitif olan 23, klinik ve radyolojik bulgularla COVID-19 tanısı almış 22 kanser hastası alındı. Hastaların BT görüntüleri iki radyolog tarafından eşzamanlı değerlendirildi. Komorbid hastalık varlığı, semptomlar ve laboratuvar değerleri değerlendirildi.
Bulgular: En sık BT tutulum paterni %88,9 (n=40) ile periferaldi. Bilateral akciğer tutulumu oranı %57,8 (n=26) idi. En sık saptanan bulgu buzlu cam dansiteleri idi (n=38, %84,5). Bunların %35,5 (n=16)’ine konsolidasyon da eşlik etmekteydi. Vakaların %62,2 (n=28)’sinde multifokal tutulum mevcuttu. En sık tutulan loblar alt loblar idi. Diğer nispeten sık bulgular septal kalınlaşma, subplevral çizgilenme ve hava bronkogramı idi. Hastaların ortanca nötrofil, lenfosit, D-dimer, prokalsitonin, C-reaktif protein ve laktat dehidrogenaz değerleri sırasıyla 2000 mm3, 1200 mm3, 1990 ng/mL, 30.7 µg/L 15.8 mg/dl, 161 IU/L idi.
Sonuç: Multifokal ve bilateral tutulum ile buzlucam dansiteleri en sık bulgulardı. Ancak genelde daha az saptanan septal kalınlaşmanın yüksek saptanması kanser hastalarında bulguların daha ciddi olabileceğini düşündürmektedir. PCR negatif vakalarda inflamatuvar markerların birçoğu daha yüksekti. Çok merkezde daha fazla hasta ile yapılacak çalışmalar kanser hastalarındaki bulguları genel popülasyonla daha iyi karşılaştırmayı sağlayacaktır.

Keywords

COVID-19 kanser bilgisayarlı tomografi laboratuvar PCR

References

  • Ufuk F, Savas R. Chest CT features of the novel coronavirus disease (COVID-19). Turk J Med Sci. 2020;50(4):664-78.
  • Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020:382(8):727-33.
  • Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiology. 2020:296(2):E119-20.
  • Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904-13.
  • Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75.
  • Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-23.
  • Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. Eur J Cancer. 2020;135:251-9.
  • Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4.
  • Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263-73.
  • Ramtohul T, Cabel L, Paoletti X, Chiche L, Moreau P, Noret A, et al. Quantitative CT extent of lung damage in COVID-19 pneumonia is an independent risk factor for inpatient mortality in a population of cancer patients: A prospective study. Front Oncol. 2020;10:1560.
  • Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings of 919 patients. AJR Am J Roentgenol. 2020;215(1):87-93.
  • Ye Z, Zhang Y, Wang, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30(8):4381-9.
  • Chen D, Jiang X, Hong Y, Wen Z, Wei S, Peng G, et al. Can chest CT features distinguish patients with negative from those with positive initial RT-PCR results for coronavirus disease (COVID-19)? AJR Am J Roentgenol. 2020;[Epub ahead of print]. doi: 10.2214/AJR.20.23012.

Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients

Year 2020, Volume: 22 Issue: Special Issue, 56 - 60, 30.11.2020

Tolga Köşeci Ömer Kaya Okan Dilek İrfan Alişan Veysel Haksöyler Berna Bozkurt Duman Timuçin Çil

https://doi.org/10.18678/dtfd.795333

Abstract

Aim: The aim of this study was to evaluate the computed tomography (CT), clinical and laboratory findings of coronavirus disease 2019 (COVID-19) in cancer patients and to compare the findings between polymerase chain reaction (PCR) positive and negative patients.
Material and Methods: Twenty-three cancer patients with positive PCR tests and 22 diagnosed as COVID-19 with clinical and radiological findings were included in the study. CT images of the patients were evaluated simultaneously by two radiologists. Presence of comorbid diseases, symptoms and laboratory values were evaluated.
Results: The most common CT involvement pattern was peripheral with 88.9% (n=40). Bilateral lung involvement rate was 57.8% (n=26). The most common finding was ground glass opacities (n=38, 84.5%). 35.6% (n=16) of these were accompanied by consolidation. Multifocal involvement was present in 62.2% (n=28) of the cases. The most frequently involved lobes were lower lobes. Other relatively common findings were septal thickening, subpleural streaking, and air bronchogram. The median neutrophil, lymphocyte, D-dimer, procalcitonin, C-reactive protein and lactate dehydrogenase values of the patients were 2000 mm3, 1200 mm3, 1990 ng/mL, 30.7 mcg/L 15.8 mg/dl, 161 IU/L, respectively.
Conclusion: Multifocal and bilateral involvement, and ground glass opacities were the most common findings. However, higher rates of septal thickening, which is generally less common, suggest that the findings may be more severe in cancer patients. Most of the inflammatory markers were higher in PCR negative cases. Studies with more patients in multiple centers will provide better comparison of the findings in cancer patients with the general population.

Keywords

COVID-19 cancer computed tomography laboratory PCR

References

  • Ufuk F, Savas R. Chest CT features of the novel coronavirus disease (COVID-19). Turk J Med Sci. 2020;50(4):664-78.
  • Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020:382(8):727-33.
  • Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiology. 2020:296(2):E119-20.
  • Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904-13.
  • Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75.
  • Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-23.
  • Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. Eur J Cancer. 2020;135:251-9.
  • Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4.
  • Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263-73.
  • Ramtohul T, Cabel L, Paoletti X, Chiche L, Moreau P, Noret A, et al. Quantitative CT extent of lung damage in COVID-19 pneumonia is an independent risk factor for inpatient mortality in a population of cancer patients: A prospective study. Front Oncol. 2020;10:1560.
  • Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings of 919 patients. AJR Am J Roentgenol. 2020;215(1):87-93.
  • Ye Z, Zhang Y, Wang, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30(8):4381-9.
  • Chen D, Jiang X, Hong Y, Wen Z, Wei S, Peng G, et al. Can chest CT features distinguish patients with negative from those with positive initial RT-PCR results for coronavirus disease (COVID-19)? AJR Am J Roentgenol. 2020;[Epub ahead of print]. doi: 10.2214/AJR.20.23012.
There are 13 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Article
Authors

Tolga Köşeci 0000-0002-8696-0525

Ömer Kaya 0000-0001-7998-0686

Okan Dilek 0000-0002-2144-2460

İrfan Alişan This is me 0000-0002-9473-9476

Veysel Haksöyler This is me 0000-0001-5124-8362

Berna Bozkurt Duman 0000-0002-9889-1897

Timuçin Çil 0000-0002-5033-1479

Publication Date November 30, 2020
Submission Date September 15, 2020
Published in Issue Year 2020 Volume: 22 Issue: Special Issue

Cite

APA Köşeci, T., Kaya, Ö., Dilek, O., Alişan, İ., et al. (2020). Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Medical Journal, 22(Special Issue), 56-60. https://doi.org/10.18678/dtfd.795333
AMA Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. November 2020;22(Special Issue):56-60. doi:10.18678/dtfd.795333
Chicago Köşeci, Tolga, Ömer Kaya, Okan Dilek, İrfan Alişan, Veysel Haksöyler, Berna Bozkurt Duman, and Timuçin Çil. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal 22, no. Special Issue (November 2020): 56-60. https://doi.org/10.18678/dtfd.795333.
EndNote Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T (November 1, 2020) Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Medical Journal 22 Special Issue 56–60.
IEEE T. Köşeci, “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”, Duzce Med J, vol. 22, no. Special Issue, pp. 56–60, 2020, doi: 10.18678/dtfd.795333.
ISNAD Köşeci, Tolga et al. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal 22/Special Issue (November 2020), 56-60. https://doi.org/10.18678/dtfd.795333.
JAMA Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. 2020;22:56–60.
MLA Köşeci, Tolga et al. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal, vol. 22, no. Special Issue, 2020, pp. 56-60, doi:10.18678/dtfd.795333.
Vancouver Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. 2020;22(Special Issue):56-60.
 Download Cover Image
Creative Commons License
Duzce Medical Journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.